Patients treated with both TVR and BOC (<1%), with diagnosis or treatment for HIV (2%), or Hepatitis B (6%) were excluded. Incident treatment-related side effects were identified during f/u by pharmacy claims and ICD-9, CPT, HCPCS and revenue Vincristine solubility dmso codes, excluding patients with b/l evidence. Per-member-per-month (PMPM) treatment costs (2012 $US) were calculated as the difference between b/l and f/u PMPM costs to adjust for differences in baseline health care costs with costs during the 1 month prior to treatment initiation included as f/u costs to incorporate costs of treatment
preparation. Generalized linear models estimated costs of side effects controlling for demographics, treatment history and regimen, b/l Charlson comorbidity index, and other f/u treatment-related side-effects. Of the 1,146 patients identified, treatment regimens were 22% PR, 12% BOC+PR and 65% TVR+PR. Unadjusted incremental PMPM f/u costs were $4,706 overall; $1,576 PR, $3,979 Selleckchem CH5424802 BOC+PR and $5,915 TVR+PR. Cumulative incidence (%) and PMPM covariate-adjusted f/u costs ($) of side effects were: rash (14%, $4,402), anemia (46%, $5,403), neutropenia (16%, $5,795),
TCP (11%, $5,906), depression (23%, $5,024), anxiety (23%, $5,371), fatigue (6%, $5,180) and GI disorders (15%, $4,932). PMPM costs were significantly higher (p<0.0001) compared to patients without the condition for anemia (cost difference: $1,226), neutropenia ($1,244) and TCP ($1,290). The burden of HCV treatment-related side effects, especially anemia, is high. After adjusting for patient characteristics and other side effects associated with treatment, anemia, neutropenia and TCP result in significantly higher costs during the year following treatment
initiation relative to patients without these conditions. Disclosures: Ami R. Buikema – Employment: Optum Lisa C. Rosenblatt – Employment: Bristol-Myers Squibb; Stock Shareholder: Bristol-Myers Squibb Fang Liu – Employment: OPTUM Boris Gorsh – Employment: Bristol-Myers Squibb Bruce E. Sill – Employment: Bristol-Myers Squibb; Stock Shareholder: Bristol-Myers Squibb The following people have nothing to disclose: John C. MCE White Backgrounds: While numerous new therapeutic regimens of direct-acting antivirals (DAAs) with or without interferon (IFN) are developing, optimization of current regimens and influence of resistance-associated variants (RAVs) among difficult-to-treat patients are important for considering future treatment. Here, we have investigated host and viral genetic factors and drug adherence for their association with responses to telaprevir (TVR) or simeprevir (SMV) with PEG-IFN plus ribavirin (RBV). Patients and Methods: We analyzed 212 chronic hepatitis C patients who received PEG-IFN/RBV/TVR therapy, and 104 patients who received PEG-IFN/RBV/SMV therapy. We analyzed viral and host factors including RAVs, the numbers of core aa 70 mutations and SNPs near the IL28B gene. RAVs were analyzed by both direct and deep sequencing.